Press release
Geographic Atrophy Clinical Trial Analysis: 25+ Drugs, 23+ Companies Redefining the Future of Treatment, analyses DelveInsight
Geographic Atrophy Clinical Trial Analysis
Explore the latest pipeline developments, clinical progress, and innovation trends here: Geographic Atrophy Pipeline Outlook Report - https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Highlights from the Geographic Atrophy Pipeline Report
• November 10, 2025: Astellas Pharma Inc. announced a clinical study enrolling Japanese patients aged 40 years and older diagnosed with geographic atrophy. The study aims to assess the safety and tolerability of ASP3021, administered as monthly intravitreal injections over a 12-month period.
• November 7, 2025: Janssen Research & Development LLC initiated a clinical trial evaluating changes in GA lesion progression in eyes treated with JNJ-81201887, compared against a sham-treated control group.
• DelveInsight highlights a highly active and competitive R&D ecosystem, with more than 23 companies advancing over 25 therapeutic candidates for the treatment of Geographic Atrophy.
• Key players shaping the Geographic Atrophy pipeline include Ionis Pharmaceuticals, IVERIC bio, Apellis Pharmaceuticals, NGM Biopharmaceuticals, Annexon, Genentech, Alexion AstraZeneca Rare Disease, ONL Therapeutics, Alkeus Pharmaceuticals, Regenerative Patch Technologies, Astellas Pharma Inc., Gemini Therapeutics, Boehringer Ingelheim, Cell Cure Neurosciences, Stealth BioTherapeutics, Hemera Biosciences, Gyroscope Therapeutics, Eyevensys, Nanoscope Therapeutics, Catalyst Biosciences, Novartis, among others.
• Promising Geographic Atrophy pipeline assets include OCU410, SAR446597, BI 1584862, Tinlarebant, OpRegen, Vonaprument, NGM621, Prednisone, ANX007, and several others.
Learn more about the companies advancing innovation in GA treatment here: Geographic Atrophy Clinical Trials Assessment - https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Geographic Atrophy Pipeline Overview
The report presents a holistic disease overview, a detailed pipeline analysis, and a comprehensive evaluation of emerging therapies, with particular focus on the significant unmet needs that continue to define the Geographic Atrophy treatment landscape.
Geographic Atrophy - Disease Summary
Geographic atrophy represents an advanced stage of age-related macular degeneration (AMD) and is marked by progressive degeneration of macular tissue, including the retinal pigment epithelium, photoreceptors, and choriocapillaris. The disease typically originates in the perifoveal region and gradually spreads toward the fovea, resulting in central visual field loss and permanent vision impairment. GA is generally bilateral in nature and progresses steadily over time.
Profiles of Emerging Geographic Atrophy Therapies
IONIS-FB-LRx - Ionis Pharmaceuticals
IONIS-FB-LRx is a ligand-conjugated antisense oligonucleotide therapy designed to target complement factor B (FB). Dysregulated activation of the complement pathway-particularly FB-has been strongly associated with complement-driven diseases such as GA. By suppressing FB production, IONIS-FB-LRx aims to slow disease progression and mitigate retinal damage.
Zimura - IVERIC bio
Zimura (avacincaptad pegol) is engineered to inhibit cleavage of complement component C5, thereby reducing downstream inflammatory signaling and cellular injury. By limiting the generation of C5a and C5b, the therapy may decrease membrane attack complex (MAC) formation and help delay degeneration of retinal pigment epithelial cells in GA patients.
Track ongoing clinical trials and pipeline advancements here: Geographic Atrophy Treatment Drugs - https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Detailed Insights Offered by the Geographic Atrophy Pipeline Report
• In-depth company profiles highlighting GA-focused development strategies and asset portfolios
• Classification of pipeline drugs across early-, mid-, and late-stage development
• Assessment of active, inactive, and discontinued programs
• Segmentation of investigational therapies by route of administration (oral, parenteral, intravitreal, subretinal, topical), mechanism of action, molecular type, and monotherapy versus combination approaches
• Strategic analysis of industry partnerships, academic collaborations, licensing agreements, and funding activities supporting GA innovation
Key Companies in the Geographic Atrophy Pipeline
Ionis Pharmaceuticals, IVERIC bio, Apellis Pharmaceuticals, NGM Biopharmaceuticals, Annexon, Genentech, Alexion AstraZeneca Rare Disease, ONL Therapeutics, Alkeus Pharmaceuticals, Regenerative Patch Technologies, Astellas Pharma Inc., Gemini Therapeutics, Boehringer Ingelheim, Cell Cure Neurosciences, Stealth BioTherapeutics, Hemera Biosciences, Gyroscope Therapeutics, Eyevensys, Nanoscope Therapeutics, Catalyst Biosciences, Novartis, and others.
Drug Classification in the Geographic Atrophy Pipeline
Geographic Atrophy by Route of Administration (RoA)
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
Geographic Atrophy by Molecule Type
• Monoclonal antibodies
• Peptides
• Polymers
• Small molecules
• Gene therapies
Geographic Atrophy by Product Type
• Monotherapy
• Combination therapy
• Hybrid (mono/combination) approaches
Explore market drivers, challenges, and future opportunities here: Geographic Atrophy Market Perspectives - https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Geographic Atrophy Pipeline Report
• Geographical Coverage: Global
• Companies Covered: Ionis Pharmaceuticals, IVERIC bio, Apellis Pharmaceuticals, Inc., NGM Biopharmaceuticals, Annexon Inc., Genentech, Alexion AstraZeneca Rare Disease, ONL Therapeutics, Alkeus Pharmaceuticals, Regenerative Patch Technologies, LLC, Astellas Pharma Inc., Gemini Therapeutics, Boehringer Ingelheim, Cell Cure Neurosciences LTD, Stealth BioTherapeutics Inc., Hemera Biosciences LLC, Gyroscope Therapeutics Limited, Eyevensys, Nanoscope Therapeutics, Inc., Catalyst Biosciences, Novartis, and others
• Therapies Covered: OCU410, SAR446597, BI 1584862, Tinlarebant, OpRegen, Vonaprument, NGM621, Prednisone, ANX007, and others
• Therapeutic Assessment by Product Type: Monotherapy, combination therapy, mono/combination
• Therapeutic Assessment by Clinical Stage: Discovery, preclinical, Phase I, Phase II, Phase III
Stay updated on emerging GA therapies and competitive intelligence insights: Geographic Atrophy Emerging Drugs & Major Players - https://www.delveinsight.com/sample-request/geographic-atrophy-ga-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Contact Us:
Ankit Nigam
Manager - Marketing
info@delveinsight.com
+1-469-945-7679
About DelveInsight
DelveInsight is a leading life sciences market research and business consulting firm, known for its syndicated industry reports and customized strategic solutions supporting decision-making across the global healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Geographic Atrophy Clinical Trial Analysis: 25+ Drugs, 23+ Companies Redefining the Future of Treatment, analyses DelveInsight here
News-ID: 4345159 • Views: …
More Releases from DelveInsight Business Research
Interstitial Lung Disease Clinical Trial Analysis: 120+ Drugs and 120+ Companies …
DelveInsight, a prominent market intelligence and consulting organization in the life sciences domain, has announced the launch of its newest report titled "Interstitial Lung Disease Pipeline Insight, 2025." The publication delivers a comprehensive analysis of the fast-advancing therapeutic environment for Interstitial Lung Disease (ILD). With over 120 biopharmaceutical companies actively developing 120+ pipeline assets, the ILD pipeline is witnessing remarkable growth fueled by strong scientific innovation, clinical progress, and regulatory…
Global Vein Illumination Devices Market Forecast to Reach USD 152.83 Million by …
DelveInsight's latest publication, "Vein Illumination Devices Market Insights, Competitive Landscape and Market Forecast-2032," offers a comprehensive analysis of existing and future market dynamics. The report examines evolving trends, technological advancements, key market challenges, growth catalysts, and limiting factors, while also showcasing upcoming product launches and profiling the major players influencing the vein illumination devices industry.
Based on DelveInsight's most recent evaluation, the global vein illumination devices market is anticipated to experience…
Liver Cancer Clinical Trial Analysis: 75+ Drugs, 70+ Companies Redefining the Fu …
DelveInsight's "Liver Cancer Pipeline Insights 2025" delivers an in-depth overview of the liver cancer pipeline ecosystem, profiling more than 70 companies and 75+ therapeutic candidates under development. The report thoroughly examines liver cancer drug profiles across both clinical and preclinical stages. It also evaluates the therapeutic landscape by product category, development phase, route of administration, and molecular class, while additionally identifying inactive and discontinued assets within the pipeline.
Stay informed with…
Limbal Stem Cell Deficiency Market to Surpass USD 2.6 Billion by 2034, Driven by …
In 2023, the Limbal Stem Cell Deficiency (LSCD) market was dominated by the United States, generating nearly USD 1.5 billion in revenue, while Spain represented the smallest market with approximately USD 127 million. This regional distribution is expected to remain consistent throughout the forecast timeline. The US accounted for nearly 103,000 diagnosed LSCD cases, whereas Japan recorded around 37,000 cases, with both countries projected to witness notable growth in patient…
More Releases for Geographic
Geographic Information System (GIS) Software Global Market Report 2024 - Geograp …
"The Business Research Company recently released a comprehensive report on the Global Geographic Information System (GIS) Software Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The…
Cybersecurity Market Regional Analysis | Evaluating Geographic Trends
Cybersecurity Market Scope and Overview
In the digital era, where information is the new currency, cybersecurity emerges as a paramount concern for individuals, businesses, and governments alike. With the exponential growth of cyber threats, the global Cybersecurity Market has witnessed a surge in demand for innovative solutions and services to safeguard sensitive data and critical infrastructure. This report delves into a comprehensive analysis of the cybersecurity market, covering key players, market…
Geographic Information System - Comprehensive Analysis
GIS is used to power millions of decisions every day all over the world, such as examining crime patterns, pinpointing novel store locations, directing in-car navigation, and predicting and forecasting the weather, among others. The growing demand for location-based analytics among businesses to enhance operational efficiency and improve decision-making is driving the market growth. Similarly, the necessity to combine traditional data with three-dimensional data to get valuable insights from location-based…
Automobile Accessories Market: Charting New Geographic Territory
An extensive analysis of the Automobile Accessories market strategy of the leading companies in the precision of import/export consumption, supply and demand figures, cost, price, revenue and gross margins. The report starts by an introduction about the company profiling and a comprehensive review about the strategy concept and the tools that can be used to assess and analyze strategy. It also analyzes the company’s strategy in the light of Porter’s…
Geographic Atrophy - Pipeline Review, H2 2018 - ResearchByMarkets.com
"Geographic Atrophy - Pipeline Review, H2 2018", provides an overview of the Geographic Atrophy (Ophthalmology) pipeline landscape.
Geographic atrophy is an advanced form of age-related macular degeneration that can result in the progressive and irreversible loss of retina which can lead to a loss of visual function over time. Symptoms include difficulty during reading. Risk factors include smoking, thyroid hormones or antacids and in patients with coronary heart diseases and cataract…
MapsOfWorld.com partners with National Geographic Maps
MapsOfWorld.com has proudly partnered with National Geographic Maps to sell National Geographic maps and atlases in the United States. All wall maps are available at an initial discount of 15%, along with additional discounts on bulk items ordered by corporations and schools. Range of products available for sale include: paper and laminated wall maps, mural (wall paper) maps, travel maps and atlases. Wall maps are available in National Geographic’s three…
